Variable | Coefficient (SE) | 95% Confidence interval | P-value |
---|---|---|---|
Log alanine amino transferase longitudinal sub-model | |||
 Maternal age | 0.0006 (0.0023) | −0.0040, 0.0051 | 0.810 |
 Treatment | |||
  ASAQ | −0.0016 (0.0276) | −0.0557, 0.0525 | 0.953 |
  DHAPQ | 0.0031 (0.0275) | −0.0508, 0.0570 | 0.909 |
 Second trimester | −0.0223 (0.0311) | −0.0833, 0.0387 | 0.474 |
 Constant | 2.8236 (0.0608) | 2.7043, 2.9428 | < 0.001 |
Log total bilirubin longitudinal sub-model | |||
 Maternal age | −0.0027 (0.0034) | −0.0094, 0.0039 | 0.418 |
 Treatment | |||
  ASAQ | −0.0346 (0.0419) | −0.1168, 0.0476 | 0.409 |
  DHAPQ | −0.0483 (0.0416) | −0.1299, 0.0334 | 0.246 |
 Second trimester | −0.1747 (0.0471) | −0.2669, − 0.0824 | < 0.001 |
 Constant | 2.3118 (0.0911) | 2.1394, 2.4966 | < 0.001 |
Concomitant medication count sub-model | |||
 Maternal age | 0.0144 (0.0088) | −0.0030, 0.0318 | 0.103 |
 Treatment | |||
  ASAQ | −0.3469 (0.1068) | −0. 5563, − 0. 1376 | 0.001 |
  DHAPQ | −0.2850 (0.1046) | − 0.4901, − 0.0798 | 0.006 |
 Second trimester | 0.3850 (0.1273) | 0.1355, 0.6344 | 0.002 |
 Constant | −0.6712 (0.2385) | −1.1387, − 0.2038 | 0.005 |
Adverse events count sub-model | |||
 Maternal age | 0.0161 (0.0092) | 0.0019, 0.0340 | 0.079 |
 Treatment | |||
  ASAQ | 0.1687 (0.1099) | 0.0466, 0.3840 | 0.125 |
  DHAPQ | −0.0876 (0.1103) | − 0.3038, 0.1286 | 0.427 |
 Second trimester | 0.3986 (0.1270) | 0.1497, 0.6474 | 0.002 |
  αlog(ALT) | 0.0016 (0.2392) | −0.4673, 0.4704 | 0.995 |
  αlog(bilirubin) | 0.0218 (0.1207) | −0.2148, 0.2585 | 0.856 |
  αconcmed | 1.2969 (0.0837) | 1.1328, 1.4609 | < 0.001 |
  Constant | −0.6805 (0.7793) | −2.2079, 0.8469 | 0.383 |
Patient-specific random effects standard deviations | |||
 Standard deviations | |||
  δlog(ALT) | 0.2555 (0.0119) | 0.2331, 0.2800 |  |
  δlog(bilirubin) | 0.5028 (0.0153) | 0.4736, 0.5338 |  |
  δlog(concmed) | 0.7931 (0.0480) | 0.7043, 0.8931 |  |